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supports the routine use of esophagectomy for these patients.
There are inherent inaccuracies in trying to determine the
precise location of the GEJ and the relationship of the epi-
center of a cancer to the GEJ. Given these difficulties and
the lack of a significant difference in the biologic behavior
between adenocarcinoma of the DE and GEJ, we suggest
that efforts to determine the precise origin of the tumor are
not necessary and that an esophagectomy, preferably an en
bloc resection, is appropriate surgical therapy for adenocar-
cinoma in either location.
We thank Linda Chan from the University of Southern Califor-
nia for her dedicated support and advice regarding statistical
analysis and methodology in this article.
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Dr Thomas W. Rice (Cleveland, Ohio). Confusion and contro-
versy surrounds the esophagogastric junction. I would like to thank
Dr Leers and her colleagues for presenting this most important
analysis of their experience with the surgical treatment of cancers
of the esophagogastric junction. It is reports such as this that will
shed light on this contentious transition area of the upper gastroin-
testinal tract, help end therapeutic disputes, and guide us in the
treatment of cancers arising in this borderland.
This 10-cm/4-inch segment of the DE and proximal stomach has
been classified into 3 areas by Dr Siewert and his colleagues. Im-
portantly, their classification is based on pathologic assessment
of the epicenter of the tumor, an easy thing to do in the quiet of
the pathology laboratory. However, if this information is to be clin-
ically important, it must be available before treatment in the living,
swallowing world of the esophagoscopy suite. Dr Leers and her
colleagues rightly determined Siewert type at initial endoscopy.
They point out the difficulty of defining the esophagogastric junc-
tion endoscopically but have rigorously attempted to type these
cancers in 613 patients. Not surprisingly, every sixth patient defied
classification. At first, I wondered how these missing data should
have been handled in the analysis, but it became evident that these
96 unclassifiable patients represented an interesting quasi–control
group for your analysis. Although it might require propensity scor-
ing, because these are typically larger tumors, it would strengthen
your argument if patients with unclassifiable tumors had a survival
similar to that of patients from either classifiable group.
My first question is this: Have you or will you add this group to
your analysis?
Dr DeMeester. Thanks, Tom. Yes, we actually did that. The
same thought struck us, so we plotted the Kaplan–Meier survival
for those patients, and it is identical. It actually falls right in be-
tween the 2 lines for DE and GEJ tumors. Therefore we looked
at that. There was some debate within our group as to whether it
was legitimate to include those patients because, as we said, we
could not really fit them into either the DE or GEJ group, and
whether their addition just muddied the waters was a concern.
Therefore the final decision was to leave them out. But it is certainly
an interesting point, and at least now in the discussion it will be ev-
ident to everybody that the survival for these unclassified tumors
falls right in between the lines for the other 2 groups.ardiovascular Surgery c Volume 138, Number 3 601
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SDrRice. Siewert and associates have demonstrated that as Siewert
tumor type increases from I to II to III, cancers have a higher T,
a higherN, a higherM, higher histologic grade, andmore cancer-pos-
itive nodes. Although your data only include two thirds of this classi-
fication schema, if you look carefully, type II cancers compared with
type I cancers have a significantly higher T, 7%more N1, and 4% of
cancers with 5 or more positive lymph nodes, and at 5 years, there is
a 7% difference in survival. You claim that these groups are similar,
but they are systematically slightly different, and these differences
might be masked to some extent by the group composition.
I have 2 questions. Have you considered the addition of histo-
logic grade, as has Siewert, that would allow for more equal group
comparisons? And to permit a fair comparison of these retrospec-
tive data, have you considered matching patients, such as with
propensity scores, allowing risk adjustment and therefore analysis
of comparable groups that differ only by the Siewert tumor type?
Dr DeMeester. It is an interesting issue. The debate about
whether tumor grade is important or not is really, I think, coming
to the forefront when you look at early tumors. Ell and colleagues
suggested that well-differentiated tumors should be treated differ-
ently than poorly differentiated tumors. In my own practice,
when you have a reasonably sized mass, it has not made a differ-
ence, and at this point, I do not factor tumor grade in when I do
endoscopic mucosal resection as therapy for these early tumors.
Therefore it is not clear that it is an important distinction, although
it is something to consider.
In terms of further forms of analysis, I think that we could
certainly do some type of matching, but I think the difference
that you are seeing is that patients who have intestinal metaplasia
in the esophagus (ie, Barrett’s esophagus) receive surveillance,
and that is why there is a slightly higher incidence of early tumors
in that group of patients because there is a number that receive sur-
veillance and are discovered, which is becoming a bigger number
every year. The gastroenterologists in particular have not ascribed
intestinal metaplasia limited to the GEJ as a premalignant condition
that should be followed, and increasingly, there is evidence now
that that is the precursor of adenocarcinoma of the GEJ. I personally
believe those patients should be followed as well, and maybe we
would discover some of these tumors before they present with dys-
phagia and more advanced tumors. Therefore I think the explana-
tion for more T4 disease and the more advanced stages with GEJ
tumors is they are not in a surveillance program in most circum-
stances. We could certainly try to do a more detailed matching of
the 2 groups, but I am of the belief that the more statistics you
have to use to prove something, the less likely it really is a signifi-
cant difference. It came out as no difference with very easy statis-
tics, and I believe that is the real situation.
Dr Rice. But your groups might not be completely comparable.
Dr DeMeester. I think they are perfectly comparable.
Dr Rice. We can agree to disagree.
Finally, in multivariable analysis Siewert and associates have
shown that Siewert tumor type is not a predictor of survival, as
you have found. Your analysis, however, does not include a multi-
variable analysis. Powerful support of your argument that type I
and type II tumors are similar would be gained if a multivariable
analysis of matched patients demonstrated that Siewert tumor
type was not a significant variable predicting outcome. My fourth602 The Journal of Thoracic and Cardiovascular Suquestion is this: Will you include this important multivariable anal-
ysis in your report?
Dr DeMeester. Well, again, we could try to look at that, but to
do a multivariable analysis, you have to have significant differences
on univariate analysis. There was no difference really in the lymph
node prevalence of metastases. There is no difference in survival by
means of Kaplan–Meier/log-rank analysis. Therefore, again,
although you and Dr Blackstone need to be commended, I think
if you need a lot of statistics to prove a point, then there are some
questions about how significant that point is. It was very clear
that these 2 groups came out together. We can certainly do that,
but, again, I do not see that we are going to change anything.
Dr Rice.Well, the way that would help you is if you prove that
T, N,M, G, and number of lymph nodes are very, very important, as
we all know.
Dr DeMeester. We know that, Tom. We know that. That has
been proved over and over.
Dr Rice. But then you show that there is no room left to tell us
that Siewert tumor type is significant, and you will help bury this
archaic and not helpful classification.
Thank you.
Dr DeMeester. Thanks. We can certainly consider it.
DrMark J. Krasna.(Towson, Md) Tom, I have just a few ques-
tions regarding lymph nodes. Your colleague did a great presenta-
tion. Surprisingly, though, the overall prevalence of lymph node
metastasis was roughly 50% in the chest and 50% in the abdomen.
Therefore one question is this: Can you explain the lower incidence
of lymph node involvement than seen in some of the other reported
series, where it approaches 75% to 85%? Was there a high use, for
instance, of neoadjuvant therapy in your series?
Dr DeMeester. No. Neoadjuvant therapy was 18% in each
group, and when we looked at node distribution and prevalence
of lymph nodes, it was only in the en bloc group without neoadju-
vant therapy so as not to confuse the issue of where nodes were and
so forth.
Dr Krasna. Second, just to follow up on that, I was impressed
that the celiac node involvement number was actually quite low.
It was only about 10% in one group and a little bit more in the other.
Is there an aversion in your group to include patients who have pos-
itive celiac nodes, or is that simply what your finding is at the time
of your en bloc resection? The reason I ask is this. As we have heard
from the proposed new staging system, celiac node involvement
will be like any other node involvement in the future, and if there
is an aversion to operate on such patients, there apparently is no
clear-cut evidence that that is correct. Therefore I am curious about
your philosophy.
Dr DeMeester. No, we have no aversion to that. In fact, we
published years ago that the presence of celiac node involvement
has absolutely no bearing on survival. If you look at celiac node
involvement in the context of the number of involved nodes, you
will find it is the number of involved nodes that predicts survival.
The celiac node itself is meaningless. Therefore I would prefer to
have 1 celiac node positive than to have 5 nonceliac nodes pos-
itive. I would take the first choice any day of the week. Therefore
it is the number of involved nodes and not the distribution that is
important. We have no qualms about taking out celiac nodal
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